Ask Google

Results for inferioritetsmarginer translation from Danish to English

Human contributions

From professional translators, enterprises, web pages and freely available translation repositories.

Add a translation

Danish

English

Info

Danish

Forskellene lå dog inden for de prædefinerede ækvivalensmarginer (ENGAGE og ENSURE) eller non-inferioritetsmarginer (PURSUE).

English

However, the differences were within the predefined equivalence (ENGAGE and ENSURE) or non-inferiority (PURSUE) margins.

Last Update: 2017-04-26
Usage Frequency: 1
Quality:

Danish

Behandling med Eperzan mødte ikke den præspecificerede non-inferioritetsmargin for HbA1c til liraglutid (se tabel 8).

English

Treatment with Eperzan did not meet the pre-specified noninferiority margin (0.3%) against liraglutide for HbA1c (see Table 8).

Last Update: 2017-04-26
Usage Frequency: 1
Quality:

Danish

Behandling med Eperzan opfyldte ikke den prædefinerede non-inferioritetsmargin (0,3 %) for HbA1c mod pioglitazon.

English

Treatment with Eperzan did not meet the pre-specified noninferiority margin (0.3%) against pioglitazone for HbA1c.

Last Update: 2017-04-26
Usage Frequency: 1
Quality:

Danish

Den nedre grænse for konfidensintervallet på 95 % lå over den prædefinerede non-inferioritetsmargin på -10 %, og viste derfor non-inferioritet.

English

The lower limit of the 95% CI was above the predefined non-inferiority margin of -10%, proving non-inferiority.

Last Update: 2017-04-26
Usage Frequency: 5
Quality:

Danish

Den præspecificerede non-inferioritetsmargin for behandlingsforskel var 20%.

English

The prespecified non-inferiority margin for the treatment difference was 20%.

Last Update: 2017-04-26
Usage Frequency: 1
Quality:

Danish

Der blev udført en efterfølgende non- inferioritetsanalyse for PFS og OS med en præspecificeret non-inferioritetsmargin på 15 %.

English

A non-inferiority analysis was conducted for PFS and OS, with a pre-specified non-inferiority margin of 15%.

Last Update: 2017-04-26
Usage Frequency: 1
Quality:

Danish

Edoxaban 60 mg var non-inferior i forhold til warfarin for det primære endepunkt for virkning apopleksianfald eller SEE (øvre grænse for 97,5 % CI for HR var under den præspecificerede non-inferioritetsmargin på 1,38) (tabel 4).

English

Edoxaban 60 mg was non-inferior to warfarin for the primary efficacy endpoint of stroke or SEE (upper limit of the 97.5% CI of the HR was below the pre- specified non-inferiority margin of 1.38) (Table 4).

Last Update: 2017-04-26
Usage Frequency: 1
Quality:

Danish

Forkortelser: CI = konfidensinterval, DVT = dyb venetrombose, mITT = modificeret intention-to- treat, HR = Hazard Ratio vs. warfarin, n = antal personer med hændelser, N = antal personer i mITT- population, LE = lungeemboli, VTE = venøse tromboemboliske hændelser. a Det primære endepunkt for virkning er adjudikeret symptomatisk, recidiverende VTE (det vil sige det sammensatte endepunkt med DVT, ikke-dødelig LE og dødelig LE). b Det tosidede CI for HR er baseret på Cox proportional hazards-regressionsmodellen, der inkluderer behandling og følgende stratificeringsfaktorer for randomisering som kovarianser: foreliggende diagnose (LE med eller uden DVT, kun DVT), risikofaktorer ved baseline (midlertidige faktorer, alle andre) og behovet for 30 mg edoxaban/edoxaban placebo-dosis ved randomisering (ja/nej). c p-værdien er for den prædefinerede non-inferioritetsmargin på 1,5.

English

Abbreviations: CI = Confidence Interval; DVT = deep vein thrombosis; mITT = modified intent-to- treat; HR = Hazard Ratio vs. warfarin; n = number of subjects with events; N = number of subjects in mITT population; PE = pulmonary embolism; VTE = venous thromboembolic events. a The primary efficacy endpoint is adjudicated symptomatic recurrent VTE (i.e., the composite endpoint of DVT, non-fatal PE, and fatal PE). b The HR, two-sided CI are based on the Cox proportional hazards regression model including treatment and the following randomisation stratification factors as covariates: presenting diagnosis (PE with or without DVT, DVT only), baseline risk factors (temporary factors, all others), and the need for 30 mg edoxaban/edoxaban placebo dose at randomisation (yes/no). c The p-value is for the pre-defined non-inferiority margin of 1.5.

Last Update: 2017-04-26
Usage Frequency: 1
Quality:

Danish

Non-inferioritetsmargin

English

non-inferiority margin

Last Update: 2017-04-26
Usage Frequency: 1
Quality:

Danish

RE-MEDY viste, at behandling med dabigatranetexilat 150 mg 2 gange dagligt er non-inferior i forhold til warfarin; non-inferioritetsmargin: 2,85 for hazard ratio og 2,8 i risiko-forskel.

English

RE-MEDY demonstrated that treatment with dabigatran etexilate 150 mg twice daily was non-inferior to warfarin (non-inferiority margin 2.85 for hazard ratio and 2.8 for risk difference).

Last Update: 2017-04-26
Usage Frequency: 1
Quality:

Danish

Studierne viste, at glykæmisk kontrol (HbA1c) med Levemir er sammenlignelig med den, der opnås med NPH-insulin og insulin degludec givet som basalbolus-behandling, ved brug af en non-inferioritetsmargin på 0,4%.

English

The trials demonstrated that glycaemic control (HbA1c) with Levemir is comparable to NPH insulin and insulin degludec when given as basal-bolus therapy, using a non- inferiority margin of 0.4%.

Last Update: 2017-04-26
Usage Frequency: 1
Quality:

Danish

Ved uge 26 var behandlingsforskellen i HbA1c mellem Eperzan og insulin lispro 0,2 % og opfyldte den prædefinerede non-inferioritetsmargin (0,4 %).

English

At 26 weeks, the between-treatment difference in HbA1c of 0.2% for Eperzan and insulin lispro met the pre-specified noninferiority margin (0.4%).

Last Update: 2017-04-26
Usage Frequency: 1
Quality:

Danish

Ved uge 52 var behandlingsforskellen i HbA1c mellem Eperzan og insulin glargin 0,1 % (-0,04, 0,27) i forhold til baseline, og opfyldte den prædefinerede non- inferioritetsmargin (0,3 %).

English

The between-treatment difference in HbA1c of 0.1% (-0.04, 0.27) from baseline at 52 weeks for Eperzan and insulin glargine met the pre- specified noninferiority margin (0.3%).

Last Update: 2017-04-26
Usage Frequency: 1
Quality:

Danish

Værst tænkelige ekstrapolering a Der blev vist non-inferioritet, idet den nedre grænse (3,2%) var højere end den forud fastsatte non- inferioritetsmargin (20%). b Konfidensintervallet på 95,1% afspejler et yderligere 0,001 alfa for at tage højde for en interims-effektanalyse.

English

a Non-inferiority was demonstrated since the lower bound (  3.2%) was higher than the pre-determined non-inferiority margin (  20%). b The 95.1% confidence level reflects an additional 0.001 alpha to account for an interim efficacy analysis.

Last Update: 2017-04-26
Usage Frequency: 1
Quality:

Danish

a En person kan være repræsenteret i flere rækker. b Hændelsesraten (%/år) er beregnet som antal hændelser/personårs-eksponering. c Den tosidede p-værdi er baseret på non-inferioritetsmarginen på 1,38.

English

a A subject can be represented in multiple rows. b The event rate (%/yr) is calculated as number of events/subject-year exposure. c The two-sided p-value is based on the non-inferiority margin of 1.38.

Last Update: 2017-04-26
Usage Frequency: 1
Quality:

Danish

b LS-middelværdi (SE). c Non-inferioritet blev testet ved anvendelse af en præspecificeret, fast non-inferioritetsmargin på 4% på dag 28 i cyklus 1. d Estimater blev opnået fra en Cox proportional hazards-regressionsmodel. e P-værdi bestemt ved anvendelse af en log-rank-test.

English

b LS Mean (SE). c Non-inferiority was tested using a pre-specified, fixed non-inferiority margin of 4% at Day 28 of Cycle 1. d Estimates were obtained from a Cox proportional hazards regression model. e P-value determined using a log-rank test.

Last Update: 2017-04-26
Usage Frequency: 1
Quality:

Danish

Der blev anvendt en non- inferioritetsmargin på 0, 4 log10 kopier/ ml.

English

The primary analysis assessed the non- inferiority of APV/ r to the SOC PI group with respect to time-weighted average change from baseline (AAUCMB) in plasma viral load (HIV-1 RNA) at week 16 using a non-inferiority margin of 0.4 log10 copies/ ml.

Last Update: 2011-10-23
Usage Frequency: 1
Quality:

Warning: This alignment may be wrong.
Please delete it you feel so.

Danish

Den primære analyse undersøgte non-inferioriteten af APV/r over for SOC-PI-gruppen med hensyn til den tidsvægtede gennemsnitlige ændring fra baseline (AAUCMB) i plasma viral load (HIV-1-RNA) ved uge 16.Der blev anvendt en non-inferioritetsmargin på 0, 4 log10 kopier/ml.

English

The primary analysis assessed the non-inferiority of APV/r to the SOC PI group with respect to time-weighted average change from baseline (AAUCMB) in plasma viral load (HIV-1 RNA) at week 16 using a non-inferiority margin of 0.4 log10 copies/ml.

Last Update: 2008-03-04
Usage Frequency: 3
Quality:

Warning: This alignment may be wrong.
Please delete it you feel so.

Get a better translation with
4,401,923,520 human contributions

Users are now asking for help:



We use cookies to enhance your experience. By continuing to visit this site you agree to our use of cookies. Learn more. OK